Based on the MR networks described above (Figure 7), we hypothesized that the simultaneously use of MR and downstream kinase inhibitors will improve potency and therefore searched for LC patients with common upregulation of these therapeutic targets. This evidence concerns the gene NR3C2 and laryngotracheoesophageal cleft.